GenSight Biologics Financial and Business Update

GenSight Biologics, a company specializing in gene therapies for retinal neurodegenerative diseases, reported a cash position of €0.9 million as of March 31, 2025, down from €2.5 million at the end of 2024. The company’s funds will cover operations until early June 2025, with planned fundraising activities to extend this runway. These efforts are critical for initiating the RECOVER Phase III trial and advancing the MHRA marketing application for LUMEVOQ®.

Discussions with French agency ANSM on an early access program for LUMEVOQ® are ongoing. The program aims to support clinical and regulatory activities by securing a financial solution that maintains cash flow. The company is also preparing to align the RECOVER study design with FDA and EMA feedback, targeting trial initiation in the first half of 2026.

By strategically exploring financing options including potential partnerships or M&A opportunities, GenSight Biologics aims to address anticipated 2026 financial commitments related to the AAC program. The company reaffirms its commitment to responsible financial management amid these challenges and opportunities.